204 followers
Protocol of a RCT that started in May: ravulizumab, a long-acting anti-complement (C5) mAb, in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome https://t.co/ON57DkLiBg
Protocol of a RCT that started in May: ravulizumab, a long-acting anti-complement (C5) mAb, in patients with COVID-19 severe pneumonia, acute lung injury, or acute respiratory distress syndrome https://t.co/ON57DkLiBg